Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria T Abreu

Showing results (141-150 of 219) with videos related to

Pageof 22
Sort By:
Pharmaceuticals (Basel, Switzerland)|November 27, 2024
Oxidized Low-Density Lipoprotein Induces Reactive Oxygen Species-Dependent Proliferation of Intestinal Epithelial CellsEddy E Gonzalez-Horta, Juan F Burgueno, María J Leiva, et al.
Journal of Crohn'S & Colitis|February 4, 2024
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative ColitisSubrata Ghosh, Brian G Feagan, Elyssa Ott, et al.
The American Journal of Gastroenterology|May 19, 2023
Patients With Inflammatory Bowel Diseases and Higher Visceral Adipose Tissue Burden May Benefit From Higher Infliximab Concentrations to Achieve RemissionAndres J Yarur, Maria T Abreu, Parakkal Deepak, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 11, 2022
Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI TrialSilvio Danese, Bruce E Sands, Maria T Abreu, et al.
The American Journal of Gastroenterology|October 11, 2008
Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trialJames F Marion, Jerome D Waye, Daniel H Present, et al.
Digestive Diseases and Sciences|July 9, 2018
Hispanics Coming to the US Adopt US Cultural Behaviors and Eat Less Healthy: Implications for Development of Inflammatory Bowel DiseaseOriana M Damas, Derek Estes, Danny Avalos, et al.
Journal of Crohn'S & Colitis|May 3, 2024
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical ProgrammeMiguel Regueiro, Britta Siegmund, Andres J Yarur, et al.
The American Journal of Gastroenterology|August 13, 2021
A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel DiseaseAdam S Cheifetz, Maria T Abreu, Waqqas Afif, et al.
Gastroenterology|February 6, 2004
Association of antibody responses to microbial antigens and complications of small bowel Crohn's diseaseWilliam S Mow, Eric A Vasiliauskas, Ying-Chao Lin, et al.
Inflammatory Bowel Diseases|June 20, 2024
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical ProgramVipul Jairath, David T Rubin, Bram Verstockt, et al.
Pageof 22

Showing results (141-150 of 219) with videos related to

Sort By:
Pageof 22
Pharmaceuticals (Basel, Switzerland)|November 27, 2024
Oxidized Low-Density Lipoprotein Induces Reactive Oxygen Species-Dependent Proliferation of Intestinal Epithelial CellsEddy E Gonzalez-Horta, Juan F Burgueno, María J Leiva, et al.
Journal of Crohn'S & Colitis|February 4, 2024
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative ColitisSubrata Ghosh, Brian G Feagan, Elyssa Ott, et al.
The American Journal of Gastroenterology|May 19, 2023
Patients With Inflammatory Bowel Diseases and Higher Visceral Adipose Tissue Burden May Benefit From Higher Infliximab Concentrations to Achieve RemissionAndres J Yarur, Maria T Abreu, Parakkal Deepak, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 11, 2022
Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI TrialSilvio Danese, Bruce E Sands, Maria T Abreu, et al.
The American Journal of Gastroenterology|October 11, 2008
Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trialJames F Marion, Jerome D Waye, Daniel H Present, et al.
Digestive Diseases and Sciences|July 9, 2018
Hispanics Coming to the US Adopt US Cultural Behaviors and Eat Less Healthy: Implications for Development of Inflammatory Bowel DiseaseOriana M Damas, Derek Estes, Danny Avalos, et al.
Journal of Crohn'S & Colitis|May 3, 2024
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical ProgrammeMiguel Regueiro, Britta Siegmund, Andres J Yarur, et al.
The American Journal of Gastroenterology|August 13, 2021
A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel DiseaseAdam S Cheifetz, Maria T Abreu, Waqqas Afif, et al.
Gastroenterology|February 6, 2004
Association of antibody responses to microbial antigens and complications of small bowel Crohn's diseaseWilliam S Mow, Eric A Vasiliauskas, Ying-Chao Lin, et al.
Inflammatory Bowel Diseases|June 20, 2024
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical ProgramVipul Jairath, David T Rubin, Bram Verstockt, et al.
Pageof 22